Keros Therapeutics, Inc. (KROS)
| Market Cap | 214.73M -53.7% |
| Revenue (ttm) | 15.01M -93.6% |
| Net Income | -83.16M |
| EPS | -3.10 |
| Shares Out | 19.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,334 |
| Open | 10.78 |
| Previous Close | 10.76 |
| Day's Range | 10.78 - 11.11 |
| 52-Week Range | 9.69 - 22.55 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 19.83 (+83.1%) |
| Est. Earnings | Nov 17, 2026 |
About KROS
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KROS stock is "Buy." The 12-month stock price target is $19.83, which is an increase of 83.10% from the latest price.
News
Keros Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
Eleriscept’s Phase III program with Takeda could yield data around 2028–2029, while its milestone supports runway into H2 2028. Rinvatercept DMD data are expected from H1 2027, and an ALS Phase II trial is planned to start in 2027.
Keros Therapeutics to receive $20M development milestone payment from Takeda
Keros Therapeutics (KROS) announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda (TAK), following ...
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel thera...
Keros announces first patient dosed in Phase 2 trial of rinvatercept
Keros Therapeutics (KROS) announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel thera...
Keros Therapeutics files $350M mixed securities shelf
16:04 EDT Keros Therapeutics (KROS) files $350M mixed securities shelf
Keros Therapeutics Registration statement: Registration filing
Keros Therapeutics filed a registration statement on September 10, 2026, providing details about a securities offering with the SEC.
Keros Therapeutics announces $5M share repurchase program after Takeda payment
Keros Therapeutics (KROS) announced that its board of directors has approved a $5M share repurchase program of the company’s common stock following receipt of a $20M development milestone payment unde...
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercial...
Keros Therapeutics price target lowered to $17 from $20 at BofA
BofA lowered the firm’s price target on Keros Therapeutics (KROS) to $17 from $20 and keeps a Neutral rating on the shares after updating the firm’s model to reflect the…
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
Wells Fargo analyst Benjamin Burnett lowered the firm’s price target on Keros Therapeutics (KROS) to $18 from $20 and keeps an Overweight rating on the shares. The firm notes shares…
Keros Therapeutics price target lowered to $23 from $30 at Leerink
Leerink lowered the firm’s price target on Keros Therapeutics (KROS) to $23 from $30 and keeps an Outperform rating on the shares.
Keros Therapeutics reports Q2 EPS ($1.45), consensus ($1.24)
“We are excited to have initiated our Phase 2 clinical trial evaluating the treatment of rinvatercept in patients with Duchenne muscular dystrophy, marking an important milestone in the development of...
Keros Therapeutics Reports Second Quarter 2026 Financial Results
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Earnings release: Q2 2026
Keros Therapeutics released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Keros Therapeutics Quarterly report: Q2 2026
Keros Therapeutics has published its Q2 2026 quarterly earnings report on August 3, 2026.
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
Keros Therapeutics (KROS) announced that it will receive a $20M development milestone payment under the terms of the license agreement of elritercept with partner Takeda (TAK), following the dosing of...
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...
Keros Therapeutics Appoints Anne Prener to its Board of Directors
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commerciali...
Keros Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing KER-065 for DMD, targeting muscle regeneration and bone health, with phase II data expected in 2027. Financially, it is well-funded through H1 2028, with additional pipeline expansion into ALS and a lucrative partnership with Takeda for elritercept.
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therap...
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
Reports Q1 revenue $367,000, consensus $1.69M. “Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities,” said Jasbir S. Seehra, P...
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results
LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializ...
Keros Therapeutics Earnings release: Q1 2026
Keros Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Keros Therapeutics Quarterly report: Q1 2026
Keros Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.